• STAT+: Arcus' anti-TIGIT immunotherapy shows ‘encouraging' tumor response, but likely leaves investors wanting more

    1 month ago - By STAT

    Arcus Biosciences said Wednesday that a two-drug combination that includes an anti-TIGIT antibody delivered “encouraging clinical activity” following a preliminary look at a clinical trial of patients with lung cancer.
    Beyond a verbal description of the interim study results, however, the Hayward, Calif.-based biotech isn't saying much about its closely tracked TIGIT immunotherapy, called domvanalimab. Gilead Sciences has an option to license domvanalimab, but is deferring a decision until later this year, Arcus said Wednesday. Continue to STAT+ to read the full story...
    Read more ...